ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
Oncology-Inspired Treatment Options for COVID-19.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Aspects and prospects of preclinical theranostic radiopharmaceutical development.Theranostics · 2024Review
- New hybrid radio-fluorescent probes [Heliyon · 2023Article
- SARS-CoV-2 receptor binding domain radio-probe: a non-invasive approach for angiotensin-converting enzyme 2 mapping in mice.Acta pharmacologica Sinica · 2022Article
- Article
- The Impact of COVID-19 on Nuclear Medicine Operations Including Cardiovascular Manifestations in the USA.Seminars in nuclear medicine · 2022Review
- Reply: Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2.ACS pharmacology & translational science · 2021Review
- Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics.Pharmaceutics · 2020Review
- Rapid detection of SARS-CoV-2 using a radiolabeled antibody.Nuclear medicine and biologyArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
CR3022 is a human antibody that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we explore the use of CR3022 as a molecularly targeted radiotherapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.